Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5705188 | Ophthalmology | 2017 | 12 Pages |
Abstract
CXL is cost-effective compared with conventional management with PKP in the treatment of keratoconus. Our ICER of Can$9090/QALY falls well below the range of Can$20â000 to Can$100â000/QALY and below US$50â000/QALY, thresholds generally used to evaluate the cost-effectiveness of health interventions in Canada and the United States. This study provides strong economic evidence for the cost-effectiveness of early CXL in keratoconus.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Victoria C. MD, Petros MSc, PhD, Hall F. MD, FRCSC, Wendy OD, MSc,